8-K: NWBio Completes Advent BioServices Acquisition

Northwest Biotherapeutics, Inc. has finalized its acquisition of Advent BioServices Ltd., gaining assets and recovering 19 million securities.

Summary

• Northwest Biotherapeutics, Inc. (NWBio) has completed the acquisition of Advent BioServices Ltd. (Advent).
• Advent is now a wholly owned subsidiary of NWBio.
• NWBio acquired Advent's fixed assets, including extensive cryostorage and other equipment, as well as intellectual property and other intangibles.
• NWBio is not issuing any new shares or other securities in connection with acquiring Advent.
• 19 million NWBio securities (13.5 million shares and 5.5 million options) previously issued to Advent for contract services are reverting back to NWBio.
• The consideration for the acquisition includes a payment of $1.4 million and the net amount of accounts payable (Net AP) already due from NWBio to Advent for services.
• The consideration will be paid in installments over two years, with potential acceleration after regulatory approval of NWBio's DCVax-L product.
• Installment payments will not begin until 90 days after the October closing date, rather than 90 days after the August agreement, and Net AP is determined as of the closing date.

Sentiment

Score: 8

Explanation: The acquisition is highly favorable due to the recovery of a significant number of securities and the strategic gain of assets without issuing new shares, despite the cash payment obligation.

Positives

• Acquisition of extensive fixed assets, including cryostorage and equipment, enhancing operational capabilities.
• Acquisition of intellectual property and other intangibles from Advent.
• No new shares or securities are being issued for the acquisition, avoiding dilution.
• 19 million NWBio securities (13.5 million shares and 5.5 million options) are reverting back to the company, reducing outstanding securities.
• Payment for the acquisition is structured in installments over two years, providing financial flexibility.
• Potential for accelerated payments after regulatory approval of DCVax-L suggests confidence in the product's future.

Negatives

• NWBio is obligated to pay $1.4 million plus net accounts payable to Advent, representing a cash outflow.
• The payment schedule, while flexible, still represents a future financial commitment.

Future Outlook

The consideration for the acquisition has potential for acceleration after regulatory approval of the company's DCVax-L product, indicating a forward-looking expectation for product approval.

Management Comments

• Northwest Biotherapeutics, Inc. (OTCQB:NWBO), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. has closed.

Industry Context

This acquisition strengthens NWBio's infrastructure and intellectual property in the personalized immune therapy space, a growing segment within oncology. By integrating Advent's cryostorage and equipment, NWBio enhances its capabilities for developing and potentially commercializing its DCVax platform, aligning with the industry trend towards advanced biomanufacturing and supply chain control for complex biological products.

Comparison to Industry Standards

• The recovery of previously issued securities is a unique and highly favorable aspect, contrasting with typical acquisitions where new shares are often issued, leading to dilution. This structure is not common in standard M&A deals.
• The payment structure, tied to regulatory approval, is a common risk-sharing mechanism seen in biotech acquisitions, particularly for companies with products in late-stage development, similar to earn-out provisions.
• Acquiring key operational assets like cryostorage is a strategic move for biotech companies to control their supply chain and manufacturing, a practice observed in companies like Kite Pharma (acquired by Gilead) or Juno Therapeutics (acquired by Celgene) which built or acquired significant manufacturing capabilities.

Related Party Transactions

• The acquisition of Advent BioServices Ltd. could be considered a related party transaction given that NWBio previously issued securities to Advent as payment for contract services, indicating a pre-existing business relationship.

Stakeholder Impact

• Shareholders: Positive impact due to the recovery of 19 million securities (reducing potential dilution) and the strategic acquisition of assets without issuing new shares.
• Employees: Advent employees are now part of NWBio, potentially leading to integration and new opportunities.
• Customers: Enhanced capabilities (e.g., cryostorage) could benefit future customers of DCVax-L.
• Creditors: The $1.4 million payment and net accounts payable represent a financial obligation, but the structured payment over two years mitigates immediate cash flow impact.

Next Steps

• Commencement of installment payments 90 days after the October closing.
• Potential acceleration of payments after regulatory approval of DCVax-L product.

Key Dates

Recommendation

The acquisition is highly favorable for Northwest Biotherapeutics. The company is gaining significant fixed assets, intellectual property, and operational capabilities by making a cash payment and assuming existing payables, but crucially, it is not issuing new shares. Furthermore, 19 million previously issued NWBio securities (13.5 million shares and 5.5 million options) are reverting back to the company. This effectively reduces the outstanding share count and option overhang, which is a strong positive for existing shareholders and future valuation. The structured payment over two years and the link to DCVax-L regulatory approval also demonstrate prudent financial management and confidence in their pipeline. This transaction significantly strengthens the company's position without diluting shareholder value, making it a strong positive catalyst.

Keywords

Northwest Biotherapeutics, NWBO, Advent BioServices, Acquisition, Biotechnology, DCVax, Immune Therapies, Solid Tumor Cancers, Cryostorage, Intellectual Property, SEC Filing, 8-K